FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3217102938> ?p ?o ?g. }

• W3217102938 endingPage "101218" @default.
• W3217102938 startingPage "101218" @default.
• W3217102938 abstract "This phase 2/3 immunobridging study evaluated the safety and immunogenicity of the ChAdOx1 nCoV-19 Coronavirus Vaccine (Recombinant) (SII-ChAdOx1 nCoV-19), manufactured in India at the Serum Institute of India Pvt Ltd (SIIPL), following technology transfer from the AstraZeneca.This participant-blind, observer-blind study randomised participants 3:1 to SII-ChAdOx1 nCoV-19 or AZD1222 (ChAdOx1 nCoV-19) (immunogenicity/reactogenicity cohort) and 3:1 to SII-ChAdOx1 nCoV-19 or placebo (safety cohort). The study participants were enrolled from 14 hospitals across India between August 25 and October 31, 2020. Two doses of study products were given 4 weeks apart. The primary objectives were to demonstrate non-inferiority of SII-ChAdOx1 nCoV-19 to AZD1222 in terms of geometric mean titre (GMT) ratio of anti-SARS-CoV-2 spike IgG antibodies 28 days after the second dose (defined as lower limit of 95% CI >0·67) and to determine the incidence of serious adverse events (SAEs) causally related to SII-ChAdOx1 nCoV-19. The anti-spike IgG response was assessed using a multiplexed electrochemiluminescence-based immunoassay. Safety follow-up continued until 6 months after first dose. Trial registration: CTRI/2020/08/027170.1601 participants were enrolled: 401 to the immunogenicity/reactogenicity cohort and 1200 to the safety cohort. After two doses, seroconversion rates for anti-spike IgG antibodies were more than 98·0% in both the groups. SII-ChAdOx1 nCoV-19 was non-inferior to AZD1222 (GMT ratio 0·98; 95% CI 0·78-1·23). SAEs were reported in ≤ 2·0% participants across the three groups; none were causally related. A total of 34 SARS-CoV-2 infections were reported; of which 6 occurred more than 2 weeks after the second dose; none were severe.SII-ChAdOx1 nCoV-19 has a non-inferior immune response compared to AZD1222 and an acceptable safety/reactogenicity profile. Pharmacovigilance should be maintained to detect any safety signals.SIIPL funded the contract research organisation and laboratory costs, while the site costs were funded by the Indian Council of Medical Research. The study vaccines were supplied by SIIPL and AstraZeneca." @default.
• W3217102938 created "2021-12-06" @default.
• W3217102938 creator A5002153399 @default.
• W3217102938 creator A5006042494 @default.
• W3217102938 creator A5008896575 @default.
• W3217102938 creator A5011095860 @default.
• W3217102938 creator A5012677170 @default.
• W3217102938 creator A5015076763 @default.
• W3217102938 creator A5015247025 @default.
• W3217102938 creator A5024884485 @default.
• W3217102938 creator A5029404552 @default.
• W3217102938 creator A5036804381 @default.
• W3217102938 creator A5042324494 @default.
• W3217102938 creator A5047138862 @default.
• W3217102938 creator A5051476386 @default.
• W3217102938 creator A5055179202 @default.
• W3217102938 creator A5056011565 @default.
• W3217102938 creator A5057251915 @default.
• W3217102938 creator A5058844147 @default.
• W3217102938 creator A5058974954 @default.
• W3217102938 creator A5060251393 @default.
• W3217102938 creator A5064452626 @default.
• W3217102938 creator A5064952671 @default.
• W3217102938 creator A5066948741 @default.
• W3217102938 creator A5067777800 @default.
• W3217102938 creator A5070656676 @default.
• W3217102938 creator A5072784089 @default.
• W3217102938 creator A5073417167 @default.
• W3217102938 creator A5076130506 @default.
• W3217102938 creator A5078754563 @default.
• W3217102938 creator A5079587734 @default.
• W3217102938 creator A5086034817 @default.
• W3217102938 creator A5087487607 @default.
• W3217102938 date "2021-12-01" @default.
• W3217102938 modified "2023-09-28" @default.
• W3217102938 title "A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India" @default.
• W3217102938 cites W3034858522 @default.
• W3217102938 cites W3042833857 @default.
• W3217102938 cites W3108666979 @default.
• W3217102938 cites W3111128314 @default.
• W3217102938 cites W3111590711 @default.
• W3217102938 cites W3131762051 @default.
• W3217102938 cites W3133277826 @default.
• W3217102938 cites W3139533040 @default.
• W3217102938 cites W3163312867 @default.
• W3217102938 cites W3176254064 @default.
• W3217102938 cites W3183828359 @default.
• W3217102938 cites W3184696594 @default.
• W3217102938 cites W3193887886 @default.
• W3217102938 cites W4225711802 @default.
• W3217102938 doi "https://doi.org/10.1016/j.eclinm.2021.101218" @default.
• W3217102938 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34870133" @default.
• W3217102938 hasPublicationYear "2021" @default.
• W3217102938 type Work @default.
• W3217102938 sameAs 3217102938 @default.
• W3217102938 citedByCount "14" @default.
• W3217102938 countsByYear W32171029382022 @default.
• W3217102938 countsByYear W32171029382023 @default.
• W3217102938 crossrefType "journal-article" @default.
• W3217102938 hasAuthorship W3217102938A5002153399 @default.
• W3217102938 hasAuthorship W3217102938A5006042494 @default.
• W3217102938 hasAuthorship W3217102938A5008896575 @default.
• W3217102938 hasAuthorship W3217102938A5011095860 @default.
• W3217102938 hasAuthorship W3217102938A5012677170 @default.
• W3217102938 hasAuthorship W3217102938A5015076763 @default.
• W3217102938 hasAuthorship W3217102938A5015247025 @default.
• W3217102938 hasAuthorship W3217102938A5024884485 @default.
• W3217102938 hasAuthorship W3217102938A5029404552 @default.
• W3217102938 hasAuthorship W3217102938A5036804381 @default.
• W3217102938 hasAuthorship W3217102938A5042324494 @default.
• W3217102938 hasAuthorship W3217102938A5047138862 @default.
• W3217102938 hasAuthorship W3217102938A5051476386 @default.
• W3217102938 hasAuthorship W3217102938A5055179202 @default.
• W3217102938 hasAuthorship W3217102938A5056011565 @default.
• W3217102938 hasAuthorship W3217102938A5057251915 @default.
• W3217102938 hasAuthorship W3217102938A5058844147 @default.
• W3217102938 hasAuthorship W3217102938A5058974954 @default.
• W3217102938 hasAuthorship W3217102938A5060251393 @default.
• W3217102938 hasAuthorship W3217102938A5064452626 @default.
• W3217102938 hasAuthorship W3217102938A5064952671 @default.
• W3217102938 hasAuthorship W3217102938A5066948741 @default.
• W3217102938 hasAuthorship W3217102938A5067777800 @default.
• W3217102938 hasAuthorship W3217102938A5070656676 @default.
• W3217102938 hasAuthorship W3217102938A5072784089 @default.
• W3217102938 hasAuthorship W3217102938A5073417167 @default.
• W3217102938 hasAuthorship W3217102938A5076130506 @default.
• W3217102938 hasAuthorship W3217102938A5078754563 @default.
• W3217102938 hasAuthorship W3217102938A5079587734 @default.
• W3217102938 hasAuthorship W3217102938A5086034817 @default.
• W3217102938 hasAuthorship W3217102938A5087487607 @default.
• W3217102938 hasBestOaLocation W32171029381 @default.
• W3217102938 hasConcept C126322002 @default.
• W3217102938 hasConcept C142724271 @default.
• W3217102938 hasConcept C159654299 @default.
• W3217102938 hasConcept C197934379 @default.
• W3217102938 hasConcept C203014093 @default.
• W3217102938 hasConcept C204787440 @default.
• W3217102938 hasConcept C27081682 @default.

• next